Development of TAP, a non-invasive test for qualitative and quantitative measurements of biomarkers from the skin surface

Biomarker Research

Kadri Orro¹  Olga Smirnova¹  Jelena Arshavskaja¹  Kristiina Salk¹  Anne Meikas¹  Susan Pihelgas¹  Reet Rumvolt¹  Külli Kingo²  Aram Kazarjan¹  Toomas Neuman¹  Pieter Spee³ 

[1] FibroTx LLC, Mäealuse 4, 12918 Tallinn, Estonia

[2] Dermatology Clinic, Tartu University Hospital, Raja 31, 50407 Tartu, Estonia

[3] PS! Pharmaconsult, Møllemoseparken 44, 3450 Allerød, Denmark

关键词: β-defensin-1;    CXCL-2;    CXCL-1;    Interleukin 1RA;    Interleukin 1α;    Transdermal analyses patch;    Diagnostics;    Skin care;    Dermatology;    Biomarker;   

Others  :  1084167
DOI  :  10.1186/2050-7771-2-20

 received in 2014-08-14, accepted in 2014-10-02,  发布年份 2014

【 摘 要 】

Background

The skin proteome contains valuable information on skin condition, but also on how skin may evolve in time and may respond to treatments. Despite the potential of measuring regulatory-, effector- and structural proteins in the skin for biomarker applications in clinical dermatology and skin care, convenient diagnostic tools are lacking. The aim of the present study was to develop a highly versatile and non-invasive diagnostic tool for multiplex measurements of protein biomarkers from the surface of skin.

Results

The Transdermal Analyses Patch (TAP) is a novel molecular diagnostic tool that has been developed to capture biomarkers directly from skin, which are quantitatively analyzed in spot-ELISA assays. Optimisation of protocols for TAP production and biomarker analyses makes TAP measurements highly specific and reproducible. In measurements of interleukin-1α (IL-1α), IL-1 receptor antagonist (IL-1RA) and human β-defensin (hBD-1) from healthy skin, TAP appears far more sensitive than skin lavage-based methods using ELISA. No side-effects were observed using TAP on human skin.

Conclusion

TAP is a practical and valuable new skin diagnostic tool for measuring protein-based biomarkers from skin, which is convenient to use for operators, with minimal burden for patients.

【 授权许可】

   
2014 Orro et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Chuong CM, Nickoloff BJ, Elias PM, Goldsmith LA, Macher E, Maderson PA, Sundberg JP, Tagami H, Plonka PM, Thestrup-Pederson K, Bernard BA, Schroder JM, Dotto P, Chang CM, Williams ML, Feingold KR, King LE, Kligman AM, Rees JL, Christophers E: What is the ‘true’ function of skin? Exp Dermatol 2002, 11:159-187.
• [2]Ghosh AK: Factors involved in the regulation of type I collagen gene expression: implication in fibrosis. Exp Biol Med (Maywood) 2002, 227:301-314.
• [3]Uitto J, Olsen DR, Fazio MJ: Extracellular matrix of the skin: 50 years of progress. J Invest Dermatol 1989, 92:61S-77S.
• [4]Bowden PE, Wood EJ, Cunliffe WJ: Comparison of prekeratin and keratin polypeptides in normal and psoriatic human epidermis. Biochim Biophys Acta 1983, 743:172-179.
• [5]Sun TT, Eichner R, Nelson WG, Vidrich A, Woodcock-Mitchell J: Keratin expression during normal epidermal differentiation. Curr Probl Dermatol 1983, 11:277-291.
• [6]Woodcock-Mitchell J, Eichner R, Nelson WG, Sun TT: Immunolocalization of keratin polypeptides in human epidermis using monoclonal antibodies. J Cell Biol 1982, 95:580-588.
• [7]Portugal-Cohen M, Horev L, Ruffer C, Schlippe G, Voss W, Ma’or Z, Oron M, Soroka Y, Frusic-Zlotkin M, Milner Y, Kohen R: Non-invasive skin biomarkers quantification of psoriasis and atopic dermatitis: cytokines, antioxidants and psoriatic skin auto-fluorescence. Biomed Pharmacother 2012, 66:293-299.
• [8]Bose F, Petti L, Diani M, Moscheni C, Molteni S, Altomare A, Rossi RL, Talarico D, Fontana R, Russo V, Altomare G, Reali E: Inhibition of CCR7/CCL19 axis in lesional skin is a critical event for clinical remission induced by TNF blockade in patients with psoriasis. Am J Pathol 2013, 183:413-421.
• [9]Mee JB, Corkm MJ, di Giovine FS, Duff GW, Groves RW: Interleukin-1: a key inflammatory mediator in psoriasis? Cytokine 2006, 33:72-78.
• [10]Kristensen M, Deleuran B, Eedy DJ, Feldmann M, Breathnach SM, Brennan FM: Distribution of interleukin 1 receptor antagonist protein (IRAP), interleukin 1 receptor, and interleukin 1 alpha in normal and psoriatic skin: decreased expression of IRAP in psoriatic lesional epidermis. Br J Dermatol 1992, 127:305-311.
• [11]Hammerberg C, Arend WP, Fisher GJ, Chan LS, Berger AE, Haskill JS, Voorhees JJ, Cooper KD: Interleukin-1 receptor antagonist in normal and psoriatic epidermis. J Clin Invest 1992, 90:571-583.
• [12]Cooper KD, Hammerberg C, Baadsgaard O, Elder JT, Chan LS, Sauder DN, Voorhees JJ, Fisher G: IL-1 activity is reduced in psoriatic skin: decreased IL-1 alpha and increased nonfunctional IL-1 beta. J Immunol 1990, 144:4593-4603.
• [13]McCully ML, Ladell K, Hakobyan S, Mansel RE, Price DA, Moser B: Epidermis instructs skin homing receptor expression in human T cells. Blood 2012, 120:4591-4598.
• [14]Schaerli P, Ebert L, Willimann K, Blaser A, Roos RS, Loetscher P, Moser B: A skin-selective homing mechanism for human immune surveillance T cells. J Exp Med 2004, 199:1265-1275.
• [15]Weninger W, Uthman A, Pammer J, Pichler A, Ballaun C, Lang IM, Plettenberg A, Bankl HC, Sturzl M, Tschachler E: Vascular endothelial growth factor production in normal epidermis and in benign and malignant epithelial skin tumors. Lab Invest 1996, 75:647-657.
• [16]Viac J, Palacio S, Schmitt D, Claudy A: Expression of vascular endothelial growth factor in normal epidermis, epithelial tumors and cultured keratinocytes. Arch Dermatol Res 1997, 289:158-163.
• [17]Detmar M: The role of VEGF and thrombospondins in skin angiogenesis. J Dermatol Sci 2000, 24(Suppl):S78-S84.
• [18]Ali RS, Falconer A, Ikram M, Bissett CE, Cerio R, Quinn AG: Expression of the peptide antibiotics human beta defensin-1 and human beta defensin-2 in normal human skin. J Invest Dermatol 2001, 117:106-111.
• [19]Schmitt J, Langan S, Deckert S, Svensson A, von Kobyletzki L, Thomas K, Spuls P: Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol 2013, 132:1337-1347.
• [20]Oranje AP, Glazenburg EJ, Wolkerstorfer A, de Waard-van der Spek FB: Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. Br J Dermatol 2007, 157:645-648.
• [21]Schmitt J, Wozel G: The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005, 210:194-199.
• [22]Sandby-Moller J, Wulf HC: Ultrasonographic subepidermal low-echogenic band, dependence of age and body site. Skin Res Technol 2004, 10:57-63.
• [23]El-Zawahry MB, Abdel El-Hameed El-Cheweikh HM, Abd-El-Rahman S, Ahmed Bassiouny D, Mohamed Fawzy M: Ultrasound biomicroscopy in the diagnosis of skin diseases. Eur J Dermatol 2007, 17:469-475.
• [24]Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
• [25]Malaviya R, Sun Y, Tan JK, Magliocco M, Gottlieb AB: Induction of lesional and circulating leukocyte apoptosis by infliximab in a patient with moderate to severe psoriasis. J Drugs Dermatol 2006, 9:890-893.
• [26]Frank R, Hargreaves R: Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003, 2:566-580.
• [27]Leigh IM, Navsaria H, Purkis PE, McKay IA, Bowden PE, Riddle PN: Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro. Br J Dermatol 1995, 133:501-511.
• [28]Bhawan J, Bansal C, Whren K, Schwertschlag U: K16 expression in uninvolved psoriatic skin: a possible marker of pre-clinical psoriasis. J Cutan Pathol 2004, 31:471-476.
• [29]Donetti E, Gualerzi A, Ricceri F, Pescitelli L, Bedoni M, Prignano F: Etanercept restores a differentiated keratinocyte phenotype in psoriatic human skin: a morphological study. Exp Dermatol 2012, 21:549-551.
• [30]Wilson CL, Dean D, Lane BE, Dawber PR, Leigh IM: Keratinocyte differentiation in psoriatic scalp: morphology and expression of epithelial keratins. Br J Dermatol 1994, 131:191-200.
• [31]Lemster BH, Carroll PB, Rilo HR, Johnson N, Nikaein A, Thomson AW: IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy. Clin Exp Immunol 1995, 99:148-154.
• [32]Caldarola G, De Simone C, Carbone A, Tulli A, Amerio P, Feliciani C: TNFalpha and its receptors in psoriatic skin, before and after treatment with etanercept. Int J Immunopathol Pharmacol 2009, 22:961-966.
• [33]Rashmi R, Rao KS, Basavaraj KH: A comprehensive review of biomarkers in psoriasis. Clin Exp Dermatol 2009, 34:658-663.
• [34]Li J, Chen X, Liu Z, Yue Q, Liu H: Expression of Th17 cytokines in skin lesions of patients with psoriasis. J Huazhong Univ Sci Technolog Med Sci 2007, 27:330-332.
• [35]Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suarez-Farinas M, Fuentes-Duculan J, Novitskaya I, Khatcherian A, Bluth MJ, Lowes MA, Krueger AJ: Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007, 204:3183-3194.
• [36]Antiga E, Volpi W, Chiarini C, Cardilicchia E, Fili L, Manuelli C, Parrochi P, Fabbri P, Caproni M: The role of etanercept on the expression of markers of T helper 17 cells and their precursors in skin lesions of patients with psoriasis vulgaris. Int J Immunopathol Pharmacol 2010, 23:767-774.
• [37]Portugal-Cohen M, Kohen R: Non-invasive evaluation of skin cytokines secretion: an innovative complementary method for monitoring skin disorders. Methods 2013, 61:63-68.
• [38]Portugal-Cohen M, Oron M, Ma’or Z, Boaz M, Shtendik L, Biro A, Cernes R, Barnea Z, Kazir Z, Kohen R: Noninvasive skin measurements to monitor chronic renal failure pathogenesis. Biomed Pharmacother 2011, 65:280-285.
• [39]Hendrix SW, Miller KH, Youket TE, Adam R, O’Connor RJ, Morel JG, Tepper BE: Optimization of the skin multiple analyte profile bioanalytical method for determination of skin biomarkers from D-Squame tape samples. Skin Res Technol 2007, 13:330-342.
• [40]Perkins MA, Osterhues MA, Farage MA, Robinson MK: A noninvasive method to assess skin irritation and compromised skin conditions using simple tape adsorption of molecular markers of inflammation. Skin Res Technol 2001, 7:227-237.
• [41]Perkins MA, Cardin CW, Osterhues MA, Robinson MK: A non-invasive tape absorption method for recovery of inflammatory mediators to differentiate normal from compromised scalp conditions. Skin Res Technol 2002, 8:187-193.
• [42]Gillitzer R, Ritter U, Spandau U, Goebeler M, Brocker EB: Differential expression of GRO-alpha and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo. J Invest Dermatol 1996, 107:778-782.
• [43]Kulke R, Todt-Pingel I, Rademacher D, Rowert J, Schroder JM, Christophers E: Co-localized overexpression of GRO-alpha and IL-8 mRNA is restricted to the suprapapillary layers of psoriatic lesions. J Invest Dermatol 1996, 106:526-530.
• [44]Konig A, Krenn V, Toksoy A, Gerhard N, Gillitzer R: Mig, GRO alpha and RANTES messenger RNA expression in lining layer, infiltrates and different leucocyte populations of synovial tissue from patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Virchows Arch 2000, 436:449-458.
• [45]Emson CL, Fitzmaurice S, Lindwall G, Li KW, Hellerstein MK, Maibach HI, Liao W, Turner SM: A pilot study demonstrating a non-invasive method for the measurement of protein turnover in skin disorders: application to psoriasis. Clin Transl Med 2013, 2:12. BioMed Central Full Text
• [46]Jones KD: Troubleshooting protein binding in nitrocellulose membranes, Part 1: Principles. IVD Technol 1999, 5:32-41.
• [47]Hirao T, Aoki H, Yoshida T, Sato Y, Kamoda H: Elevation of interleukin 1 receptor antagonist in the stratum corneum of sun-exposed and ultraviolet B-irradiated human skin. J Invest Dermatol 1996, 106(5):1102-1107.